Today, we look at mid-cap biotech concern Alexion Pharmaceuticals which recently delivered better than expected quarterly results. Valuation is more than reasonable, but I am concerned its franchise ...

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31 ...

Alexion Pharmaceuticals, Inc. ALXN today presented longer-term data from the extensions of two pivotal phase 2 studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome ...

Soliris® is a first-in-class complement inhibitor that works by inhibiting the terminal part of the complement cascade, a part of the immune system that, when activated in an uncontrolled manner, ...

Only hours after announcing a positive recommendation in Europe for terminal complement inhibitor Soliris (eculizumab) in atypical hemolytic uremic syndrome (aHUS), Alexion Pharmaceuticals Inc. won ...

HER ultra-rare disease could strike anyone and can kill its victims within a year. The only effective treatment is the world’s most expensive drug. Two blood transfusions saved her at the time, but 16 ...

(RTTNews) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major ...

Sept 23 (Reuters) - U.S. health regulators cleared an Alexion Pharmaceuticals drug for adults and children with a rare genetic disorder that damages vital organs, as the company expands the uses of ...

Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, Inc. ALXN, has been informed by the National Specialised Commissioning Team (NSCT) that the Ministers of Health have decided to not follow a ...

An interchangeable product can be expected to produce the same clinical result as the reference product in any given patient. The Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb ...